|
||||||||||||||||||
|
|
||||||||||||||||||
|
||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe BM8 monoclonal antibody reacts with mouse F4/80 antigen, an approximately 125 kDa transmembrane protein. The F4/80 antigen is expressed by a majority of mature macrophages and is the best marker for this population of cells. However, other cell types such as Langerhans cells and liver Kupffer cells have been reported to express this antigen. Expression of F4/80 commences during early myeloid development with approximately 30% of BM cells staining with BM8 and is upregulated on all BM cells stimulated in vitro with M-CSF. It has been shown that some cytokines downregulate the expression of F4/80 resulting in lack of F4/80 antigen on a subpopulation of macrophages, especially in the lymphoid microenvironment in vivo. Applications ReportedFor research use only, not for diagnostic or therapeutic use. BM8 has been reported for use in flow cytometric analysis. Applications TestedThe BM8 antibody has been tested by flow cytometric analysis of mouse spleen and bone marrow cell suspensions. This can be used at less than or equal to 0.5 μg per million cells in a 100 μl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. References
Schaller E, Macfarlane AJ, Rupec RA, Gordon S, McKnight AJ, Pfeffer K. 2002. Inactivation of the F4/80 glycoprotein in the mouse germ line. Mol Cell Biol. 22(22):8035-43. Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W. 1994. Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods. 174(1-2):5-19. Zwadlo G, Brocker EB, von Bassewitz DB, Feige U, Sorg C. 1985. A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol. 134(3):1487-92. Murayama, T., M. Yokode, et al. 1999. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation. 99(13):1740-6. (IHC frozen, PubMed) Geutskens, S., T. Otonkoski, et al. 2005. Macrophages in the murine pancreas and their involvement in fetal endocrine development in vitro. J Leukoc Biol. 78(4): 845-52. (IHC frozen, PubMed) Torzewski, M., P. Shaw, et al. 2004. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Aterioscler Thromb Vasc Biol. 24(12): 2307-12. (IHC paraffin, PubMed) Mackler, A., L.M. Green, et al. 2000. Distribution and activation of uterine mononuclear phagocytes in peripartum endometrium and myometrium of the mouse. Biol Reprod. 62(5):1193-200. (IHC paraffin, PubMed) Related ProductsCat. 11-4317 Streptavidin-FITC (Fluorescein isothiocyanate) Cat. 12-4317 Streptavidin-PE (Phycoerythrin) Cat. 17-4317 Streptavidin Allophycocyanin (SA-APC) Cat. 16-4321 Functional Grade Purified Rat IgG2a Isotype Control Cat. 11-4811 FITC Anti-Rat IgG Cat. 13-4813 Biotin Anti-Rat IgG (clone Polyclonal) |
||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |